LindaAnneFeaginsMDFACP, AGAF, FACP

Inflammatory Bowel Disease

Professor, Internal Medicine, University of Texas at Austin, Dell Medical School and Director, Center for Inflammatory Bowel Diseases at Dell Medical School

Join to view full profile

Dr. Feagins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feagins' full profile

Already have an account?

Office
1601 Trinity Street, Ste. 9.901S
Austin, TX 78712
Phone+1 512-324-9660

Education & Training

University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 2003 - 2007
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2001 - 2003
Baylor College of MedicineClass of 2001
Vanderbilt UniversityBE, Biomedical Engineering, Magna Cum Laude, 1993 - 1997

Certifications & Licensure

TX State Medical License 2003 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology
American Board of Internal MedicineMedicine

Clinical Trials

Exacerbating Factors in Inflammatory Bowel Disease Start of enrollment: 2009 Aug 01
Completed
Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis Start of enrollment: 2012 Jun 01
Unknown status
Phase 2
Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping Start of enrollment: 2011 Sep 01
Completed
Not Applicable
Corrona Inflammatory Bowel Disease (IBD) Registry Start of enrollment: 2017 Mar 27
Enrolling by invitation
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2019 Jun 13
Completed
Phase 3
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2019 Sep 05
Recruiting
Phase 3
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis Start of enrollment: 2020 Sep 15
Completed
Phase 3
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2020 Jan 06
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Higher rates of delay in starting advanced inflammatory bowel disease therapies linked to insurance delays, intravenous infusions, and lack of pharmacy support.
Sara Gottesman, Karen Xiao, Hang P Nguyen, Elizabeth Hernandez, Emily Saweris
Clinical and Translational Gastroenterology. 2024-12-24
1 citations
Overview of Biosimilars in Inflammatory Bowel Diseases.
Linda A Feagins, Stephanie Gold, Adam F Steinlauf,
The American Journal of Gastroenterology. 2024-02-01
4 citations
Delayed Diagnostic Paracentesis Is Associated with Increased Preventable Healthcare Utilization in Disadvantaged Patient Populations with Advanced Liver Disease and El...
Cristal Brown, Nazan Aksan, Patrick Chang, Priyanka Jagannathan, Maria Goretti Ochi
Digestive Diseases and Sciences. 2023-07-01

Authored Content

Colonoscopy, Polypectomy, and the Risk of BleedingNovember 2018
Tu1054 LOW RATES OF REBLEEDING FOR PATIENTS WHO EXPERIENCE POST-POLYPECTOMY BLEEDINGMay 2018

Press Mentions

Why Diet Absolutely Matters in Ulcerative ColitisApril 20th, 2023
Clinical Challenges: Integrating Diet into Crohn's Disease ManagementDecember 29th, 2023
Clinical Challenges: Integrating Nutrition into the Treatment of Crohn’s DiseaseDecember 31st, 2023